21 results on '"Shen, Yang"'
Search Results
2. A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease.
- Author
-
Cardoso, Francisco, Goetz, Christopher G., Mestre, Tiago A., Sampaio, Cristina, Adler, Charles H., Berg, Daniela, Bloem, Bastiaan R., Burn, David J., Fitts, Michael S., Gasser, Thomas, Klein, Christine, de Tijssen, Marina A.J., Lang, Anthony E., Lim, Shen‐Yang, Litvan, Irene, Meissner, Wassilios G., Mollenhauer, Brit, Okubadejo, Njideka, Okun, Michael S., and Postuma, Ronald B.
- Published
- 2024
- Full Text
- View/download PDF
3. Altered gut microbiome and metabolome in patients with multiple system atrophy
- Author
-
Tan, Ai Huey, Chong, Chun Wie, Song, Sze Looi, Teh, Cindy Shuan Ju, Yap, Ivan Kok Seng, Loke, Mun Fai, Tan, Yong Qi, Yong, Hoi Sen, Mahadeva, Sanjiv, Lang, Anthony E., and Lim, Shen‐Yang
- Published
- 2018
- Full Text
- View/download PDF
4. <scp> Helicobacter pylori </scp> Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial
- Author
-
Chin Khoon Ng, Mun Fai Loke, Jing Kun Lee, Wan Ting Lim, Tze Ying Ng, Jiun Yan Tan, Ai Huey Tan, Sanjiv Mahadeva, Kok Ping Chin, Ban Hong Ang, Aaron Guan Siang Tan, Susan H. Fox, Nusyaibah Zulkifli, Intan Maisara Zulkifle, Yong Teck Teo, Aimi Izzah Ibrahim, Yong Leng Kok, Connie Marras, Shawna Mei Chien Ong, Anthony E. Lang, Jamunarani Vadivelu, Shen-Yang Lim, Amni Fatihah Mohammad Adnan, Soon Sean Ee, Khairunnisa Mohamad Shukori, and Shuhaina Arafin
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Parkinson's disease ,Urea breath test ,Placebo-controlled study ,Placebo ,Helicobacter Infections ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Surveys and Questionnaires ,Internal medicine ,Small intestinal bacterial overgrowth ,medicine ,Humans ,Helicobacter pylori ,medicine.diagnostic_test ,biology ,business.industry ,Montreal Cognitive Assessment ,Parkinson Disease ,biology.organism_classification ,medicine.disease ,030104 developmental biology ,Neurology ,Concomitant ,Quality of Life ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
Background Helicobacter pylori (HP) infection has been associated with worse motor function in Parkinson's disease (PD). Objective We aimed to evaluate the effects of HP eradication on PD symptoms. Methods In this parallel-group, double-blind, randomized placebo-controlled, single-center trial, patients with PD with positive HP urea breath test and serology were block randomized (1:1) to receive standard eradication triple therapy or identically appearing placebo capsules for 1 week. Prespecified motor (International Parkinson and Movement Disorder Society Unified PD Rating Scale [MDS-UPDRS], timed tests, and home-based wearable sensor measurements), nonmotor (Leeds Dyspepsia Questionnaire and Montreal Cognitive Assessment), and quality-of-life (Parkinson's Disease Questionnaire-39) outcome measures were assessed at weeks 6, 12, 24, and 52. The primary outcome was the baseline-to-week 12 change in ON medication MDS-UPDRS motor scores. Lactulose-hydrogen breath testing for concomitant small intestinal bacterial overgrowth was performed at baseline and repeated at week 24, together with the urea breath test. Results A total of 310 patients were screened for eligibility and 80 were randomly assigned, of whom 67 were included in the full-analysis set (32 treatment group patients, 35 placebo patients). HP eradication did not improve MDS-UPDRS motor scores at week 12 (mean difference 2.6 points in favor of placebo, 95% confidence interval: -0.4 to 5.6, P = 0.089). There was no significant improvement in any motor, nonmotor, or quality-of-life outcome at weeks 12 and 52. Both the full-analysis and per-protocol analyses (based on eradication status) supported these conclusions. Small intestinal bacterial overgrowth status did not influence treatment results. Conclusions HP eradication does not improve clinical outcomes in PD, suggesting that there is no justification for routine HP screening or eradication with the goal of improving PD symptoms. © 2020 International Parkinson and Movement Disorder Society.
- Published
- 2020
5. Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions.
- Author
-
Schumacher‐Schuh, Artur Francisco, Bieger, Andrei, Okunoye, Olaitan, Mok, Kin Ying, Lim, Shen‐Yang, Bardien, Soraya, Ahmad‐Annuar, Azlina, Santos‐Lobato, Bruno Lopes, Strelow, Matheus Zschornack, Salama, Mohamed, Rao, Shilpa C., Zewde, Yared Zenebe, Dindayal, Saiesha, Azar, Jihan, Prashanth, Lingappa Kukkle, Rajan, Roopa, Noyce, Alastair J., Okubadejo, Njideka, Rizig, Mie, and Lesage, Suzanne
- Abstract
Background: Human genetics research lacks diversity; over 80% of genome‐wide association studies have been conducted on individuals of European ancestry. In addition to limiting insights regarding disease mechanisms, disproportionate representation can create disparities preventing equitable implementation of personalized medicine. Objective: This systematic review provides an overview of research involving Parkinson's disease (PD) genetics in underrepresented populations (URP) and sets a baseline to measure the future impact of current efforts in those populations. Methods: We searched PubMed and EMBASE until October 2021 using search strings for "PD," "genetics," the main "URP," and and the countries in Latin America, Caribbean, Africa, Asia, and Oceania (excluding Australia and New Zealand). Inclusion criteria were original studies, written in English, reporting genetic results on PD from non‐European populations. Two levels of independent reviewers identified and extracted information. Results: We observed imbalances in PD genetic studies among URPs. Asian participants from Greater China were described in the majority of the articles published (57%), but other populations were less well studied; for example, Blacks were represented in just 4.0% of the publications. Also, although idiopathic PD was more studied than monogenic forms of the disease, most studies analyzed a limited number of genetic variants. We identified just nine studies using a genome‐wide approach published up to 2021, including URPs. Conclusion: This review provides insight into the significant lack of population diversity in PD research highlighting the immediate need for better representation. The Global Parkinson's Genetics Program (GP2) and similar initiatives aim to impact research in URPs, and the early metrics presented here can be used to measure progress in the field of PD genetics in the future. © 2022 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
- Author
-
Brandon R. Barton, Regina Katzenschlager, Klaus Seppi, Shen-Yang Lim, Rob M.A. de Bie, Miguel Coelho, Susan H. Fox, and Cristina Sampaio
- Subjects
0301 basic medicine ,Pergolide ,Rasagiline ,Safinamide ,Rivastigmine ,medicine.medical_specialty ,Levodopa ,Parkinson's disease ,business.industry ,medicine.disease ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Physical medicine and rehabilitation ,Neurology ,Dyskinesia ,chemistry ,medicine ,Entacapone ,Neurology (clinical) ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Objective The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD). Background The Movement Disorder Society Evidence-Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016. Methods Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported. Results A total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise-based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful. Conclusions The options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society.
- Published
- 2018
7. Brief Clinical Rating Scales Should Not Be Overlooked
- Author
-
Lim, Shen‐Yang, primary, Lim, Kai Bin, additional, Hor, Jia Wei, additional, and Tan, Ai Huey, additional
- Published
- 2020
- Full Text
- View/download PDF
8. Helicobacter pyloriEradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial
- Author
-
Tan, Ai Huey, primary, Lim, Shen‐Yang, additional, Mahadeva, Sanjiv, additional, Loke, Mun Fai, additional, Tan, Jiun Yan, additional, Ang, Ban Hong, additional, Chin, Kok Ping, additional, Mohammad Adnan, Amni Fatihah, additional, Ong, Shawna Mei Chien, additional, Ibrahim, Aimi Izzah, additional, Zulkifli, Nusyaibah, additional, Lee, Jing Kun, additional, Lim, Wan Ting, additional, Teo, Yong Teck, additional, Kok, Yong Leng, additional, Ng, Tze Ying, additional, Tan, Aaron Guan Siang, additional, Zulkifle, Intan Maisara, additional, Ng, Chin Khoon, additional, Ee, Soon Sean, additional, Arafin, Shuhaina, additional, Mohamad Shukori, Khairunnisa, additional, Vadivelu, Jamunarani S., additional, Marras, Connie, additional, Fox, Susan H., additional, and Lang, Anthony E., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians.
- Author
-
Miyasaki, Janis M., Lim, Shen‐Yang, Chaudhuri, K. Ray, Antonini, Angelo, Piemonte, Maria, Richfield, Edward, Alburquerque Gonzalez, Daniela, Lorenzl, Stefan, Walker, Richard, Bhidayasiri, Roongroj, Bouca, Raquel, and McConvey, Victor
- Abstract
Background: Neuropalliative care is an emerging field for those with neurodegenerative illnesses, but access to neuropalliative care remains limited. Objective: We sought to determine Movement Disorder Society (MDS) members' attitudes and access to palliative care. Methods: A quantitative and qualitative survey instrument was developed by the MDS Palliative Care Task Force and e‐mailed to all members for completion. Descriptive statistics and qualitative analysis were triangulated. Results: Of 6442 members contacted, 652 completed the survey. Completed surveys indicating country of the respondent overwhelmingly represented middle‐ and high‐income countries. Government‐funded homecare was available to 54% of respondents based on patient need, 25% limited access, and 21% during hospitalization or an acute defined event. Eighty‐nine percent worked in multidisciplinary teams. The majority endorsed trigger‐based referrals to palliative care (75.5%), while 24.5% indicated any time after diagnosis was appropriate. Although 66% referred patients to palliative care, 34% did not refer patients. Barriers were identified by 68% of respondents, the most significant being available workforce, financial support for palliative care, and perceived knowledge of palliative care physicians specific to movement disorders. Of 499 respondents indicating their training in palliative care or desire to learn these skills, 55% indicated a desire to gain more skills. Conclusions: The majority of MDS member respondents endorsed a role for palliative care in movement disorders. Many members have palliative training or collaborate with palliative care physicians. Although significant barriers exist to access palliative care, the desire to gain more skills and education on palliative care is an opportunity for professional development within the MDS. © 2021 International Parkinson and Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinsonʼs disease
- Author
-
Fox, Susan H., Katzenschlager, Regina, Lim, Shen-Yang, Ravina, Bernard, Seppi, Klaus, Coelho, Miguel, Poewe, Werner, Rascol, Olivier, Goetz, Christopher G., and Sampaio, Cristina
- Published
- 2011
- Full Text
- View/download PDF
11. Parkinsonʼs Disease and Pain—Nondopaminergic Mechanisms are Likely to Be Important Too
- Author
-
Lim, Shen-Yang, Farrell, Michael J., and Evans, Andrew H.
- Published
- 2011
- Full Text
- View/download PDF
12. The nonmotor symptoms of Parkinsonʼs disease—An overview
- Author
-
Lim, Shen-Yang and Lang, Anthony E.
- Published
- 2010
- Full Text
- View/download PDF
13. Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2
- Author
-
Lim, Shen-Yang, Wadia, Pettarusp, Wenning, Gregor K., and Lang, Anthony E.
- Published
- 2009
- Full Text
- View/download PDF
14. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinsonʼs disease?
- Author
-
Lim, Shen-Yang, Farrell, Michael J., Gibson, Stephen J., Helme, Robert D., Lang, Anthony E., and Evans, Andrew H.
- Published
- 2008
- Full Text
- View/download PDF
15. Altered gut microbiome and metabolome in patients with multiple system atrophy
- Author
-
Hoi-Sen Yong, Yong Qi Tan, Ai Huey Tan, Cindy Shuan Ju Teh, Sze-Looi Song, Anthony E. Lang, Mun Fai Loke, Shen-Yang Lim, Ivan K. S. Yap, Sanjiv Mahadeva, and Chun Wie Chong
- Subjects
0301 basic medicine ,business.industry ,Gastrointestinal Microbiome ,RNA ,Ribosomal RNA ,Bioinformatics ,medicine.disease ,Gut microbiome ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Atrophy ,Neurology ,Metabolome ,medicine ,In patient ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Published
- 2017
16. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
- Author
-
Fox, Susan H., Katzenschlager, Regina, Lim, Shen‐Yang, Barton, Brandon, de Bie, Rob M. A., Seppi, Klaus, Coelho, Miguel, Sampaio, Cristina, on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee, Lim, Shen-Yang, and Movement Disorder Society Evidence-Based Medicine Committee
- Abstract
Objective: The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).Background: The Movement Disorder Society Evidence-Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016.Methods: Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported.Results: A total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise-based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful.Conclusions: The options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
17. Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial.
- Author
-
Tan, Ai Huey, Lim, Shen‐Yang, Mahadeva, Sanjiv, Loke, Mun Fai, Tan, Jiun Yan, Ang, Ban Hong, Chin, Kok Ping, Mohammad Adnan, Amni Fatihah, Ong, Shawna Mei Chien, Ibrahim, Aimi Izzah, Zulkifli, Nusyaibah, Lee, Jing Kun, Lim, Wan Ting, Teo, Yong Teck, Kok, Yong Leng, Ng, Tze Ying, Tan, Aaron Guan Siang, Zulkifle, Intan Maisara, Ng, Chin Khoon, and Ee, Soon Sean
- Abstract
Background: Helicobacter pylori (HP) infection has been associated with worse motor function in Parkinson's disease (PD). Objective: We aimed to evaluate the effects of HP eradication on PD symptoms. Methods: In this parallel‐group, double‐blind, randomized placebo‐controlled, single‐center trial, patients with PD with positive HP urea breath test and serology were block randomized (1:1) to receive standard eradication triple therapy or identically appearing placebo capsules for 1 week. Prespecified motor (International Parkinson and Movement Disorder Society Unified PD Rating Scale [MDS‐UPDRS], timed tests, and home‐based wearable sensor measurements), nonmotor (Leeds Dyspepsia Questionnaire and Montreal Cognitive Assessment), and quality‐of‐life (Parkinson's Disease Questionnaire‐39) outcome measures were assessed at weeks 6, 12, 24, and 52. The primary outcome was the baseline‐to‐week 12 change in ON medication MDS‐UPDRS motor scores. Lactulose‐hydrogen breath testing for concomitant small intestinal bacterial overgrowth was performed at baseline and repeated at week 24, together with the urea breath test. Results: A total of 310 patients were screened for eligibility and 80 were randomly assigned, of whom 67 were included in the full‐analysis set (32 treatment group patients, 35 placebo patients). HP eradication did not improve MDS‐UPDRS motor scores at week 12 (mean difference 2.6 points in favor of placebo, 95% confidence interval: −0.4 to 5.6, P = 0.089). There was no significant improvement in any motor, nonmotor, or quality‐of‐life outcome at weeks 12 and 52. Both the full‐analysis and per‐protocol analyses (based on eradication status) supported these conclusions. Small intestinal bacterial overgrowth status did not influence treatment results. Conclusions: HP eradication does not improve clinical outcomes in PD, suggesting that there is no justification for routine HP screening or eradication with the goal of improving PD symptoms. © 2020 International Parkinson and Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations.
- Author
-
Evans, Andrew H., Okai, David, Weintraub, Daniel, Lim, Shen‐Yang, O'Sullivan, Sean S., Voon, Valerie, Krack, Paul, Sampaio, Cristina, Post, Bart, Leentjens, Albert F.G., Martinez‐Martin, Pablo, Stebbins, Glenn T., Goetz, Christopher G., Schrag, Anette, Bhidayasiri, Roongroj, Brown, Richard G., Marinus, Johan, Mestre, Tiago A., Violante, Mayela Rodriguez, and Skorvanek, Matej
- Subjects
BEHAVIOR ,COMPULSIVE behavior ,PARKINSON'S disease ,PSYCHOLOGICAL tests ,SYSTEMATIC reviews ,DISEASE complications - Abstract
Impulse control disorders (ICDs) and related impulsive and compulsive behaviors (together called ICBs) have been increasingly recognized in the context of Parkinson's disease (PD) and treatment. The International Parkinson's and Movement Disorder Society commissioned a task force to assess available clinical screening instruments and rating scales, including their clinimetric properties, make recommendations regarding their utility, and suggest future directions in scale development and validation. The literature was systematically searched for scales measuring a range of reported ICBs in PD. A scale was designated "recommended" if the scale had been employed in PD studies, been used beyond the group that developed it, and had adequate clinimetric data published for PD. Numerous diagnostic screening tools and severity rating scales were identified for a range of ICBs, including compulsive medication use, punding/hobbyism, walkabout, pathological gambling, hypersexuality, compulsive or binge eating, compulsive buying, reckless driving, compulsive exercise, pyromania, trichotillomania, hoarding, kleptomania, intermittent explosive disorder, and internet addiction. For screening across the range of ICBs (except compulsive medication use), the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease (QUIP) and QUIP-Rating Scale (QUIP-RS) are recommended, and for severity rating across the range of ICBs the QUIP-RS and the Ardouin Scale of Behavior in Parkinson's Disease are recommended. The Scale for Outcomes in Parkinson's Disease-Psychiatric Complications is recommended for rating of hypersexuality and the compulsive behaviors gambling/shopping. Further testing of established scales against gold standard diagnostic criteria is urgently required for all other individual ICBs in PD. © 2019 International Parkinson and Movement Disorder Society © 2019 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
- Author
-
Seppi, Klaus, Ray Chaudhuri, K., Coelho, Miguel, Fox, Susan H., Katzenschlager, Regina, Perez Lloret, Santiago, Weintraub, Daniel, Sampaio, Cristina, Chahine, Lana, Hametner, Eva‐Maria, Heim, Beatrice, Lim, Shen‐Yang, Poewe, Werner, Djamshidian‐Tehrani, Atbin, and the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee, and the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee
- Abstract
Objective: To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD).Background: The International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee's recommendations for treatments of PD were first published in 2002, updated in 2011, and now updated again through December 31, 2016.Methods: Level I studies testing pharmacological, surgical, or nonpharmacological interventions for the treatment of nonmotor symptoms in PD were reviewed. Criteria for inclusion and quality scoring were as previously reported. The disorders covered were a range of neuropsychiatric symptoms, autonomic dysfunction, disorders of sleep and wakefulness, pain, fatigue, impaired olfaction, and ophthalmologic dysfunction. Clinical efficacy, implications for clinical practice, and safety conclusions are reported.Results: A total of 37 new studies qualified for review. There were no randomized controlled trials that met inclusion criteria for the treatment of anxiety disorders, rapid eye movement sleep behavior disorder, excessive sweating, impaired olfaction, or ophthalmologic dysfunction. We identified clinically useful or possibly useful interventions for the treatment of depression, apathy, impulse control and related disorders, dementia, psychosis, insomnia, daytime sleepiness, drooling, orthostatic hypotension, gastrointestinal dysfunction, urinary dysfunction, erectile dysfunction, fatigue, and pain. There were no clinically useful interventions identified to treat non-dementia-level cognitive impairment.Conclusions: The evidence base for treating a range of nonmotor symptoms in PD has grown substantially in recent years. However, treatment options overall remain limited given the high prevalence and adverse impact of these disorders, so the development and testing of new treatments for nonmotor symptoms in PD remains a top priority. © 2019 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
20. Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2
- Author
-
Anthony E. Lang, Shen-Yang Lim, Gregor K. Wenning, and Pettarusp M. Wadia
- Subjects
Pathology ,medicine.medical_specialty ,Atrophy ,Neurology ,business.industry ,Parkinsonism ,medicine ,Myotonic dystrophy type 2 ,Neurology (clinical) ,medicine.disease ,business - Published
- 2009
21. Parkinson's disease and pain-Nondopaminergic mechanisms are likely to be important too
- Author
-
Shen-Yang Lim, Michael Farrell, and Andrew Evans
- Subjects
Levodopa ,Parkinson's disease ,business.industry ,Dopaminergic ,Upper limb pain ,Disease ,medicine.disease ,Exact test ,Nociception ,Neurology ,Dyskinesia ,Anesthesia ,medicine ,Neurology (clinical) ,medicine.symptom ,business ,medicine.drug - Abstract
Anecdotally, clinicians have known that Parkinson’s disease (PD) patients may report alleviation of what appears to be pain arising from peripheral structures, in response to dopaminergic medication. Drs. Nebe and Ebersbach 1 contribute to the small literature 2 documenting this phenomenon. They report that 14 of 15 PD patients with motor fluctuations experience less intense pain (of various types, the majority with degenerative osteoarticular changes) after administration of a supra-threshold dose of levodopa (L-dopa). So-called ‘‘central’’ pain has been reported in various studies to account for as little as 0–10% of pain/sensory complaints in PD 3 ; however, central mechanisms underlying primary PD pain are also likely to mediate pain arising from peripheral structures. In a recent study, 50 PD outpatients were carefully classified according to L-dopa response (stable responders, fluctuators, and patients with dyskinesia). We reported a marked improvement in experimentally evoked pain responses after L-dopa administration in patients with dyskinesia, but not in stable responders. 4 We would like to expand on our investigations of the response of spontaneous pain to L-dopa, which were previously reported in brief only. After L-dopa challenge, we found a � 6-point reduction in Gracely pain scores (range of scale 0– 20) for spontaneous pain that was not clearly nociceptive in origin in 21 patients. Taking patients who endorsed Gracely scores � 6 in the off-medication state as the denominator, the proportion of patients whose pain improved with L-dopa was 50% (2 of 4), 89% (8 of 9), and 100% (11 of 11) for the stable responder, fluctuator, and dyskinetic groups, respectively (P ¼ 0.029, Fisher’s Exact Test). The commonest complaint was shoulder/upper limb pain (9 of 21 cases; in all but one patient
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.